{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-001898","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.096103+00:00","generated_at":"2026-05-16T11:00:34.990869+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"AIM ImmunoTech furnishes January 2026 corporate presentation","bullets":["Presentation filed as Exhibit 99.1 on Form 8-K dated January 12, 2026.","No financial results or operational milestones disclosed in the filing.","Cautionary statements reiterate risks of Ampligen development across viral, cancer, and immune indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-001898","json":"https://secwatch.observer/filing/0001493152-26-001898.json","markdown":"https://secwatch.observer/filing/0001493152-26-001898.md","text":"https://secwatch.observer/filing/0001493152-26-001898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226001898/0001493152-26-001898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226001898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:00:34.990869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}